{
    "clinical_study": {
        "@rank": "55184", 
        "acronym": "CONTAIN", 
        "arm_group": [
            {
                "arm_group_label": "Intravitreal Aflibercept Injection (x4)", 
                "arm_group_type": "Experimental", 
                "description": "2 mg / Intravitreal / every 1 month x 3 months and at month 4 (Drug administered 4 times)."
            }, 
            {
                "arm_group_label": "Intravitreal Aflibercept Injection (x6)", 
                "arm_group_type": "Experimental", 
                "description": "2 mg / Intravitreal / every 1 month x 6 months ((Drug administered 6 times)."
            }
        ], 
        "brief_summary": {
            "textblock": "A preliminary study to determine the safety and efficacy of intravitreal aflibercept\n      injection in patients with persistent central serous chorioretinopathy."
        }, 
        "brief_title": "The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Central Serous Chorioretinopathy", 
        "condition_browse": {
            "mesh_term": "Central Serous Chorioretinopathy"
        }, 
        "detailed_description": {
            "textblock": "Intravitreal Aflibercept Injection for Persistent Central Serous Chorioretinopathy: A\n      Prospective Pilot Study"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pre-treatment acuity of 20/40- 20/320\n\n          -  Macular fluid on optical coherence tomography for greater than 3 months\n\n          -  Leakage on fluorescein angiography\n\n          -  Willing and able to comply with clinic visits and study-related procedures\n\n          -  Provide signed informed consent\n\n        Exclusion Criteria:\n\n          -  Treatment for CSCR in the study eye (anti-VEGF, PDT, or laser) within three months\n             prior to study enrollment\n\n          -  Presence of choroidal neovascularization on enrollment imaging\n\n          -  Prior vitrectomy in the study eye\n\n          -  Presence of any substantial ocular disease (other than CSCR) that may compromise\n             vision in the study eye and /or confound interpretation of the data; e.g. substantial\n             cataracts, advanced glaucoma, optic neuritis, optic neuropathy or atrophy, marked\n             macular atrophy, ocular vascular occlusion, history of retinal detachment, uveitis,\n             viral or other forms of chorioretinitis, etc.\n\n          -  History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the\n             study eye\n\n          -  Uncontrolled glaucoma in the study eye (defined as IOP \u2265 25 mmHg despite treatment\n             with anti-glaucoma medication)\n\n          -  Active ocular infection or inflammation in the study eye\n\n          -  Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either\n             eye\n\n          -  Prior treatment with systemic anti-VEGF agents\n\n          -  Cerebrovascular accident or myocardial infarction within the preceding 6 months.\n\n          -  History of allergy to fluorescein, povidone iodine (Betadine) or aflibercept\n\n          -  Participation in a study of an investigational drug or device within 30 days prior to\n             potential enrollment into the study\n\n          -  Pregnant or breast-feeding women Sexually active men* or women of childbearing\n             potential** who are unwilling to practice adequate contraception during the study\n             (adequate contraceptive measures include stable use of oral contraceptives or other\n             prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to\n             screening; intrauterine device [IUD]; bilateral tubal ligation; vasectomy; condom\n             plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge,\n             foam, or jelly)\n\n               -  Contraception is not required for men with documented vasectomy.\n\n                    -  Postmenopausal women must be amenorrheic for at least 12 months in order\n                       not to be considered of child bearing potential.  Pregnancy testing and\n                       contraception are not required for women with documented hysterectomy or\n                       tubal ligation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01710332", 
            "org_study_id": "CSRII", 
            "secondary_id": "20121564"
        }, 
        "intervention": {
            "arm_group_label": [
                "Intravitreal Aflibercept Injection (x4)", 
                "Intravitreal Aflibercept Injection (x6)"
            ], 
            "description": "GROUP A - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, and Month 4 (four injections total).\nGROUP B - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, Month 3, Month 4, and Month 5 (six injections total).", 
            "intervention_name": "Intravitreal Aflibercept Injection", 
            "intervention_type": "Drug", 
            "other_name": "Eylea"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Persistent", 
            "Central", 
            "Serous", 
            "Chorioretinopathy", 
            "Regeneron", 
            "CSR", 
            "CSCR"
        ], 
        "lastchanged_date": "June 24, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Huntingdon Valley", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19006"
                    }, 
                    "name": "Mid Atlantic Retina- Huntingdon Valley"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19107"
                    }, 
                    "name": "Mid Atlantic Retna- Wills Eye Institute"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Intravitreal Aflibercept Injection for Persistent Central Serous Chorioretinopathy: A Prospective Pilot Study", 
        "overall_official": {
            "last_name": "Allen Ho, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety will be measured by the amount, significance and details of adverse events/reactions to the study drug.", 
            "measure": "Safety of intravitreal aflibercept injection", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01710332"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Wills Eye", 
            "investigator_full_name": "Brian Burke, MPH", 
            "investigator_title": "Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Mean change from baseline in best-corrected ETDRS (Early Treatment of Diabetic Retinopathy Study) letter score\nPercentage of eyes with 20/40 or better vision\nPercentage of eyes with \u2265 15-letter gain from baseline\nPercentage of eyes with < 15-letter loss from baseline", 
            "measure": "Change in vision based on letter score", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "source": "Wills Eye", 
        "sponsors": {
            "collaborator": {
                "agency": "Regeneron Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Wills Eye", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}